Full name
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants With Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
NCT Number
NCT05565378
Geography
US
Non-US
Locations
Argentina, Belgium, Brazil, Finland, France, Germany, Greece, Hungary, Italy, Japan, Republic of Korea, Mexico, Netherlands, Poland, Portugal, South Africa, Spain, Thailand, Turkey, United Arab Emirates, United Kingdom, United States
Primary Endpoints
Objective Response Rate (ORR). Up to 24 months
External Link
https://clinicaltrials.gov/study/NCT05565378
Order
0
Disease
Version
Phase
2